BW Therapeutics, Inc. announced today the opening of its Series A fundraising process and kick-off of a strategic partnering initiative. The funds raised will be used to further the development of its TYN-21 program, a novel, proprietary formulation of paclitaxel that is expected to provide equivalency to Abraxane, a leading oncology drug.

BW Therapeutics CEO and Co-Founder, Kevin Sill, Ph.D., commented, "We look forward to partnering with investors to join us in taking our TYN-21 program to the next stage and ultimately a partnership with a major biopharma partner." Brad Sullivan, Ph.D., COO and Co-Founder said, "Our market research has revealed a desire for a cost-competitive alternative to Abraxane. TYN-21 is well positioned to meet this need due to its rapid and inexpensive development path."

About BW Therapeutics:
BW Therapeutics was founded in 2019 as a biotechnology company focused on the development of TYN-21, a 505(b)(2) formulation of Abraxane. BW Therapeutics intends to develop TYN-21 through NDA approval with the proceeds from its Series A financing. 

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.